1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
China Regenerative Medicine International Limited

China Regenerative Medicine International Limited

HHKEX:8158
0.22
HKD
0.00
(0.00%)
50.20MMarket Cap
China Regenerative Medicine International Limited
HKEX:8158
(Hong Kong Exchange)

Recent

price

0.22

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
HKD
- -
0.08
- -
0.04
0.01
0.05
0.32
4.06
0.83
0.22
1.13
0.99
0.15
0.24
0.3
0.24
- -
Revenue per Share
-3.78
-1.28
-1.62
-1.66
-5.34
-4.03
-2.21
-2.1
-13.57
-4.49
-2.52
0.05
0.02
-0.38
0.06
0.09
- -
Basic EPS, GAAP
-2.34
-4.01
-0.86
-2.75
-3.01
-4.23
-1.59
-6.67
0.06
-0.33
-2.48
-0.01
-0.05
0.04
0.06
0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
14.24
11.14
9.58
13.81
13.21
21.93
23.49
21.35
6.89
1.06
0.2
0.39
0.36
0.04
0.08
0.18
0.08
Book Value per Share
-0.23
1.53
0.35
6.91
2.28
13.7
15.67
14.22
5.57
0.87
0.2
0.39
0.36
0.04
0.08
0.18
0.08
Tangible Book Value per Share
17
33
35
37
49
62
87
88
88
88
161
285
285
286
304
304
295
Basic Weighted Avg Shares
- -
3
- -
1
1
3
28
357
73
19
182
283
42
69
91
72
- -
Sales/Revenue/Turnover
-234,876.67
-1,904.96
-54,407.81
-5,407.99
-26,808.04
-6,025.52
-1,023.89
-67.35
-574.18
-449.21
-20.6
6.25
29.59
-156.97
20.37
-2.21
- -
Operating Margin (%)
18
17
18
19
30
49
52
55
70
52
2
- -
5
11
11
10
- -
Depreciation Expense
-65
-42
-57
-61
-263
-250
-191
-185
-1,194
-395
-404
13
5
-108
18
28
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
19.39
44.9
- -
- -
- -
- -
Effective Tax Rate (%)
-215,230
-1,604.77
-44,616.41
-4,453.16
-51,655.29
-8,878.17
-687.91
-51.68
-1,636.01
-2,039.79
-221.94
4.72
10.97
-154.99
19.59
38.2
- -
Profit Margin (%)
49
37
-71
204
85
1,070
1,302
841
244
43
-57
111
91
21
-1
11
35
Working Capital
- -
- -
- -
- -
- -
- -
- -
726
223
233
6
- -
14
26
45
39
22
LT Debt
414
419
353
631
780
1,844
2,118
1,908
567
18
-55
112
104
12
25
53
25
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
101.94
1.61
- -
19.77
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
20.56
3.08
- -
26.81
- -
- -
Return on Capital (%)
-23.02
-11.37
-15.63
-12.77
-37.65
-19.39
-9.87
-9.36
-96.14
-113.08
-535.56
15.72
4.22
-186.15
95.98
69.97
- -
Return on Common Equity (%)

Capital Structure

HKD

•

in mil. unless spec.
Sep'23
Dec'23
Jun'24
ST Debt
- -
24
29
LT Borrowings
- -
22
22
LT Finance Leases
- -
5
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
285
304
304
Market Capitalization
206
167
50

Working Capital

HKD

•

in mil. unless spec.
Sep'23
Dec'23
Jun'24
Total Current Assets
- -
169
133
Cash, Cash Equivalents & STI
- -
3
2
Accounts Receivable, Net
- -
1
2
Inventories
- -
- -
- -
Total Current Liabilities
- -
148
98
Payables & Accruals
- -
- -
- -
ST Debt
- -
24
29
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-74.73%
-34.47%
112.22%
Free Cash Flow
83.97%
2.81%
-77.23%
Net Income, GAAP
-223.97%
-539%
55.05%
Sales/Revenue/Turnover
280.63%
9.44%
-20.48%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
69
2024
- -
- -
91
2025
- -
- -
72

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.38
2024
- -
- -
0.06
2025
- -
- -
0.09

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
China Regenerative Medicine International Limited (8158.HK), an investment holding company listed on the GEM board of The Stock Exchange of Hong Kong Limited since 18 July 2001 and founded in 1995, is principally engaged in the provision of aesthetic medical and beauty products and services, as well as medical products and services; its core offerings include tissue-engineered products such as ActivSkin, China's only living-cell tissue-engineered skin, and Acornea, the world's first bio-engineered cornea for transplantation; bioactive cosmetics under the Aimiya brand for anti-aging and healthcare; the Ascara biomedical skincare brand developed in partnership with Switzerland's Mila D’Opiz Group; cell storage, preparation and therapy services supported by its University of Oxford Technology Centre; and hospital administration alongside overseas business activities. Headquartered at Suite 2310–2318, Miramar Tower, Tsim Sha Tsui, Kowloon, Hong Kong, the company operates seven modernized manufacturing facilities in Hong Kong, Xi’an, Shenzhen, Suzhou, Tianjin and Changzhou across China, primarily targeting healthcare providers, patients and the beauty industry in Hong Kong and the People's Republic of China. In March 2024, the group substantially modified terms on other receivables of approximately HK$236 million from a PRC service provider, derecognizing the original asset and recognizing a new interest-bearing receivable repayable in five installments through December 2028, alongside a HK$17.3 million modification loss; it continues negotiations on a December 2023 capital increase agreement for a 33.3% stake in Changzhou Bomei Biotechnology Co., Ltd. via subsidiary CRMI HK Health Technology Limited; and reported a profit of HK$17.8 million for the year ended 31 December 2024, reversing prior losses through revenue growth to HK$90.6 million driven by increased PRC visitors to its Hong Kong clinics and a HK$12.3 million expected credit loss reversal.